The deadlines and pressures are real
Regulatory deadlines are getting more stringent. Timelines to fulfill data requests are getting tighter. Pressure to uphold your company’s reputation has never been more apparent.
So what’s your best move? How do you turn the need for transparency into something of strategic value?
Sarah Lyons describes an approach to help drive your transparency goals.
“Privacy Analytics enables sponsors to deliver the insight-rich data needed to drive greater advances in patient health.”
Rebecca Li, Executive Director, Vivli, and faculty member at the Harvard Medical School Center for Bioethics
When you think about clinical trial transparency, what need comes to mind first?
Why trust Privacy Analytics with your trial transparency?
80%* of the dossiers published by EMA that used a statistical method were anonymized by Privacy Analytics.
*as of June 2020
9 of the top 10 global pharma companies listed on PharmExec’s Top 50 have trusted Privacy Analytics services.
Hundreds of clinical documents anonymized every year through the efforts of over 50 in-house experts dedicated to helping sponsors achieve transparency.
A risk-based approach protects privacy.
More proof:
As published in Trials journal (February 2020), a Novartis clinical study anonymized by Privacy Analytics for publication under EMA Policy 0070 protected privacy under a commissioned attack.
Aligned with global regulations, standards, and guidelines
Privacy Analytics provides a risk-based methodology that offers high data quality aligned with globally accepted regulations, standards and guidelines for anonymization.
This includes European Medicines Agency, EU General Data Protection Regulation, Health Canada, HIPAA, HITRUST Alliance, Institute of Medicine, and PhUSE.
